Genomics

基因组学设施的目的是提供常规和最先进的基因组技术 支持癌症中心的前沿基因组研究。常规DNA测序提供了DNA 新的DNA克隆和重组载体的序列。其他服务侧重于新的或复杂的服务 基因组技术不能在一个实验室里轻易开发，尤其是考虑到 这一技术领域的技术进步。基因组学设施已经发生了很大的变化 在过去的几年中，为了跟上中心成员不断变化的需求和 新的基因组技术。癌症中心最近购买了一个Illumina(Solexa)基因组 分析器，并通过NCI小型设备赠款，Illumina BeadStation。这笔赠款是由 癌症中心试点赠款，促进了高通量聚合酶链式反应平台的开发。该设施 被所有三个研究项目和几乎所有癌症中心的研究人员广泛使用。虽然很多人 较大的机构将测序和基因组学功能分开，该机构已经开发出一种工作 主要通过设施人员的交叉培训，有效地将服务结合在一起的模式。这 方法提供了稳定性和效率。该设施处理DNA测序和各种基因组学 将活动作为单独的服务。Illumina Genome Analyzer应用程序已添加到服务中 由基因组学机构提供。在下一个供资期间，该基金将推出多个 利用Illumina基因组分析仪和Illumina启动子监测表观遗传变化的方法 甲基化阵列。响应中心成员对microRNA(MiRNA)功能的浓厚兴趣 在发育和疾病方面，将建立一个高通量的Illumina miRNA平台，以补充 该设施目前使用的ABI低密度miRNA阵列。未来的计划还包括 开发的方案将使研究人员能够观察少数细胞中的基因表达， 比如各种类型的干细胞。

The purpose of the Genomics Facility is to provide routine and state of the art genomic technologies to support cutting edge genomics research of the Cancer Center. Routine DNA sequencing provides DNA sequence of new DNA clones and recombinant vectors. Additional services focus on new or complex genomic technologies that can not be readily developed in a single laboratory, especially given the rapid technological advancements in this technical area. The Genomics Facility has changed considerably over the past several years to keep pace with the changing needs of Center members and the rapid growth in new genomic technologies. The Cancer Center has recently purchased an Illumina (Solexa) Genome Analyzer, and, through an NCI small equipment grant, an Illumina BeadStation. This grant was facilitated by a Cancer Center pilot grant that facilitated the development of a high throughput PCR platform. The Facility is widely used by all three research programs and almost every Cancer Center investigator. Although many larger institutions separate the sequencing and genomics functions, the Facility has developed a working model to combine the services effectively, primarily through cross-training of facility personnel. This approach provides stability and efficiency. The Facility treats DNA sequencing and the various genomics activities as separate services. The Illumina Genome Analyzer applications have been added to services provided by the Genomics Facility. During the next funding period, the Facility will introduce multiple approaches to monitoring epigenetic changes with the Illumina Genome Analyzer and Illumina promoter methylation arrays. In response to a significant interest of Center members in microRNA (miRNA) functions in development and disease, a high throughput Illumina miRNA platform will be established to complement the ABI low density miRNA arrays presently being used by the facility. Future plans also include the development of protocols that will allow investigators to look at gene expression in small numbers of cells, such as various types of stem cells.